306 results about "Anaphylaxis treatment" patented technology

Devices, systems and methods for treating bronchial constriction related to asthma, anaphylaxis or chronic obstructive pulmonary disease wherein the treatment includes stimulating selected nerve fibers responsible for smooth muscle dilation at a selected region within a patient's neck, thereby reducing the magnitude of constriction of bronchial smooth muscle.

Devices, systems and methods are disclosed for treating bronchial constriction related to asthma, anaphylaxis, chronic obstructive pulmonary disease (COPD), exercise-induced bronchospasm and post-operative bronchospasm. The treatment comprises transmitting impulses of energy non-invasively to selected nerve fibers that activate neural pathways to reduce the release of acetycholine from airway-related vagal preganglionic neurons within the brain of the patient. The transmitted energy impulses, comprising magnetic and / or electrical energy, stimulate the selected nerve fibers to produce the bronchodilation.

Methods and devices for treating anaphylaxis, anaphylactic shock, bronchial constriction, and / or asthma include providing an electrical impulse to a selected region of the vagus nerve of a patient suffering from anaphylaxis to block and / or modulate nerve signals that would regulate the function of, for example, myocardial tissue, vasodilation / constriction and / or pulmonary tissue.

Devices, systems and methods are disclosed for treating bronchial constriction related to asthma, anaphylaxis or chronic obstructive pulmonary disease. The treatment comprises transmitting impulses of energy non-invasively to selected nerve fibers that are responsible for smooth muscle dilation. The transmitted energy impulses, comprising magnetic and / or electrical, mechanical and / or acoustic, and optical and / or thermal energy, stimulate the selected nerve fibers.

This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a methods of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.

Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL / sec to less than 1 mL / min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.

The invention discloses a protecting and fixing device for wound, comprising at least one protecting and fixing layer with openings, wherein the protecting and fixing layer with openings is longitudinally provided with an opening for communicating the upper end face and the lower end face; the opening can enclose the wound therein so as to make the protecting and fixing layer with openings limit the wound tension and increase the mobile corrugation of the wounded skin. The invention can protect and fix the operation wound, the trauma wound or the catheter infusion wound into an opening which can limit the tension increase of the wound and the mobile corrugation of the surface skin of the wound and can prevent the wound from being torn and cracked and also avoid the damage for the wound due to the mobile corrugation and the surgical dressing of the wounded skin as well as the relative displacement frictions of the infusion catheter. Therefore, the invention fills the blank of current technology, which can enable the covered dressings to penetratively contact the secretion so as to absorb the exudate of the wound. Besides, the invention can prevent the foreign material contact anaphylaxis due to the wound contacting by compressing the dressing and the direct bonding of the catheter infusion wound and can prevent the re-injury of the wound caused by the synechia between the dressing and the wound secretion.

Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the topical application of immunoglobulin A coupled with J chain, and optionally coupled with secretory component in order to render the immunoglobulin A more physiologically active, for the prevention or treatment of ocular diseases including ocular immune deficiency and infections. Antigen-specific monoclonal immunoglobulin A may be used.

The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.